News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates
Latest News
FDA Approves Aduhelm: Key Details on Biogen's Alzheimer's Drug
Aduhelm, recently approved by the FDA, represents a pivotal moment in Alzheimer's treatment, offering hope for patients and families affected by this devastating disease.
FDA Approves Dupixent for Eosinophilic Esophagitis Treatment
Dupixent has received FDA approval for the treatment of eosinophilic esophagitis, marking a significant advancement in managing this challenging condition.
FDA Approves Stelara: New Ulcerative Colitis Treatment from J&J
Stelara, recently approved by the FDA, provides a new treatment option for ulcerative colitis, promising improved outcomes for patients.
FDA Approves Imfinzi: Breakthrough for Stage III NSCLC Treatment
The FDA's approval of Imfinzi offers new hope for patients with Stage III non-small cell lung cancer (NSCLC), enhancing treatment possibilities.
FDA Approves Trikafta for Cystic Fibrosis in Children Ages 2-5
The FDA has approved Trikafta for the treatment of cystic fibrosis in children aged 2 to 5, marking a significant advancement in pediatric care.
FDA Approves Mounjaro: Key Details on Tirzepatide for Obesity
The FDA has officially approved Mounjaro, a new medication containing tirzepatide, for the treatment of obesity, offering hope for effective weight management.
FDA Approves Cosentyx for Moderate to Severe Hidradenitis Suppurativa
Cosentyx has received FDA approval for moderate to severe hidradenitis suppurativa, marking a significant advancement in treatment options for affected patients.
FDA Approves Moderna RSV Vaccine mRNA-1345 for Older Adults
The FDA has approved Moderna's mRNA-1345 vaccine for respiratory syncytial virus (RSV) in older adults, enhancing protection against this serious respiratory illness.
FDA Approves Zithromax for Pediatric Community-Acquired Pneumonia
The FDA has officially approved Zithromax for the treatment of pediatric community-acquired pneumonia, providing a vital option for managing this common respiratory condition in children.
FDA Priority Review Granted to CardioGen's RevivCor for Heart Failure
CardioGen's RevivCor has received FDA Priority Review status for heart failure, signaling a potential breakthrough in treatment options for patients.
FDA Approves Lumasiran for Acute Hepatic Porphyria in Adolescents
Lumasiran has received FDA approval for adolescents with Acute Hepatic Porphyria, marking a significant advancement in treatment options for this rare metabolic disorder.
FDA Approves Inhalex: New COPD Maintenance Treatment by NovaPharm
Inhalex, the latest COPD maintenance treatment by NovaPharm, has received FDA approval, promising enhanced management of chronic obstructive pulmonary disease.
FDA Approves RapidClot: Tranexamic Acid for Trauma Bleeding
The FDA has approved RapidClot, a tranexamic acid formulation, to effectively manage trauma bleeding, providing critical support in emergency medical care.
FDA Approval Tarzenta: Accelerated Approval for Advanced HER2-Negative Breast Cancer
Tarzenta has received FDA accelerated approval for the treatment of advanced HER2-negative breast cancer, marking a significant advancement in oncology care.
FDA Approves Ritempro: New Parkinson's Disease Motor Fluctuations Treatment
Ritempro has received FDA approval as a novel treatment for motor fluctuations in Parkinson's disease, promising improved management for patients.
FDA Approves Tevimbra: Breakthrough for Esophageal Squamous Cell Carcinoma
The FDA's approval of Tevimbra offers new hope for patients battling esophageal squamous cell carcinoma, representing a major breakthrough in oncology.
FDA Approves Wainua: AstraZeneca's Eplontersen for hATTR-PN
AstraZeneca's Wainua, also known as Eplontersen, has received FDA approval for the treatment of hATTR-PN, marking a significant advancement in patient care.
FDA Approves Altuviiio: Sanofi's Long-Acting Hemophilia A Therapy
Sanofi's Altuviiio has received FDA approval as a long-acting therapy for Hemophilia A, promising to revolutionize treatment for patients with this bleeding disorder.
FDA Approves Augtyro: Bristol Myers Squibb’s Repotrectinib for ROS1-NSCLC
Bristol Myers Squibb's Augtyro, a novel treatment for ROS1-positive non-small cell lung cancer, has received FDA approval, marking a significant advancement in targeted therapies.
FDA Approves Litfulo: Key Facts on Pfizer’s Alopecia Treatment
The FDA has approved Litfulo, a groundbreaking treatment by Pfizer for alopecia, offering new hope for individuals struggling with hair loss.